Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$818.93 USD

818.93
5,263,033

-10.81 (-1.30%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $816.25 -2.68 (-0.33%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AstraZeneca Sells Atacand's European Rights to Cheplapharm

AstraZeneca (AZN) sells Atacand and Atacand Plus' European rights to Cheplapharm Arzneimittel for $210 million.

    Lilly (LLY) Tops Q2 Earnings, Chooses IPO Path for Elanco

    Eli Lilly (LLY) tops estimates for both earnings and sales in the second quarter and raises guidance for 2018. It will divest its Elanco unit into a new public company. Stock up in pre-market trading.

      Eli Lilly (LLY) Tops Q2 Earnings and Revenue Estimates

      Lilly (LLY) delivered earnings and revenue surprises of 14.50% and 4.27%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

        Eli Lilly (LLY) Tops Q2 Earnings & Sales, Ups 2018 View

        Eli Lilly (LLY) beat estimates for both earnings and sales in Q2 and raised the guidance for 2018. Shares rose in pre-market trading.

          BIIB, LLY Q2 Earnings on Jul 24: Here are the Key Predictions

          Two large pharma/biotech companies have reported so far, displaying strong sales trend. Let's see how Lilly (LLY) and Biogen (BIIB) are poised ahead of their scheduled results tomorrow.

            Lilly (LLY) Issues Update on Diabetes Drug Trulicity Label

            Lilly (LLY) updates Trulicity's label to include data from a new study on patients with type II diabetes suffering from moderate to severe chronic kidney disease.

              Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals

              J&J (JNJ) and Novartis (NVS) kick off earnings for pharma sector on a strong note. FDA approves J&J's latest HIV medicine and line extension of Pfizer's prostate cancer drug.

                LLY vs. NVO: Which Stock Is the Better Value Option?

                LLY vs. NVO: Which Stock Is the Better Value Option?

                  LLY vs. NVO: Which Stock Is the Better Value Option?

                  LLY vs. NVO: Which Stock Is the Better Value Option?

                    Can Eli Lilly (LLY) Keep the Earnings Streak Alive in Q2?

                    Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.

                      Pfizer & Lilly's Pain Candidate Succeeds in Phase III Study

                      Pfizer (PFE) and Eli Lilly (LLY) announce that their investigational pain candidate, tanezumab, significantly reduces pain in osteoarthritis patients.

                        Tirthankar Chakraborty headshot

                        The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon

                        The Zacks Analyst Blog Highlights: Netflix, Eli Lilly, BNY, TJX and Raytheon

                          Mark Vickery headshot

                          Top Analyst Reports for Netflix, Eli Lilly & BNY Mellon

                          Today's Research Daily features new research reports on 16 major stocks, including Netflix (NFLX), Eli Lilly (LLY) and BNY Mellon (BK).

                            J&J's (JNJ) Invokana Label Expansion Filing Hit by FDA Delay

                            The FDA defers decision regarding label expansion application to include cardiovascular indication on the label of J&J's (JNJ) diabetes drug Invokana.

                              Mark Vickery headshot

                              Top Analyst Reports for PepsiCo, Eli Lilly & Broadcom

                              Today's Research Daily features new research reports on 16 major stocks, including PepsiCo (PEP), Eli Lilly (LLY) and Broadcom (AVGO).

                                Pfizer to Defer Price Increases After Discussion With Trump

                                Pfizer, Inc. (PFE) to defer its recent price increases of several prescription drugs after discussion with Trump.

                                  Biogen's Alzheimer Disease Candidate Succeeds in Phase II

                                  Biogen's (BIIB) Alzheimer's disease (AD) candidate demonstrates statistically significant slowdown in disease progression and reduction of amyloid beta accumulation in the brain in a phase II study.

                                    Is Pfizer's Price Hike an Effect of Drug Policy on Sector?

                                    Pfizer (PFE) reportedly raises prices of almost 100 drugs. The new drug policy has a soft stance with no provisions for direct negotiation by Medicare and resorts to competition for restricting price.

                                      Merck's Keytruda Gets Priority Review in Difficult Lung Cancer

                                      Merck's (MRK) sBLA looking to expand the label of Keytruda for first-line treatment of metastatic squamous NSCLC gets FDA's priority review. The decision is expected on Oct 30.

                                        Lilly's (LLY) Taltz Positive in Ankylosing Spondylitis Study

                                        Lilly (LLY) posts positive top-line results from a second phase III study on Taltz for the treatment of Ankylosing Spondylitis (AS).

                                          Nitish Marwah headshot

                                          Will a Trade War With China Wreak Havoc in US Healthcare?

                                          It is a known fact that Chinese investments breathe life into small and mid-scale healthcare companies in America.

                                            The Zacks Analyst Blog Highlights: Amazon, Intel, Eli Lilly, Illinois Tool Works and Southern

                                            The Zacks Analyst Blog Highlights: Amazon, Intel, Eli Lilly, Illinois Tool Works and Southern

                                              Mark Vickery headshot

                                              Top Research Reports for Amazon, Intel & Eli Lilly

                                              Today's Research Daily features new research reports on 16 major stocks, including Amazon (AMZN), Intel (INTC) and Eli Lilly (LLY).

                                                Merck's Keytruda Under FDA Review for Advanced Melanoma

                                                Merck (MRK) announces acceptance of its sBLA for Keytruda by the FDA for the treatment of patients with high-risk stage III melanoma.

                                                  Lilly's Diabetes Drugs Meet Endpoints in Phase III Studies

                                                  Lilly's (LLY) Jardiance and Humulin, being evaluated in separate phase III studies, meet primary endpoint of reduction in blood sugar level.